Aglaia Oncology Funds

Sapreme Technologies is Enabling endosomal escape of macromolecule therapeutics.

InteRNA Technologies B.V. is a biotechnology company based in Nijmegen, the Netherlands, with a research and development center in Utrecht. Founded in 2006, the company focuses on developing microRNA (miRNA)-based therapeutics aimed at treating cancer. These drugs target previously undruggable pathways, enhancing the effectiveness of existing therapies and addressing drug resistance. InteRNA employs advanced techniques such as massively parallel sequencing and proprietary bioinformatics to analyze and validate miRNA sequences. Recently, the company secured additional equity financing to further advance its lead program for melanoma treatment, reflecting its commitment to innovation in oncology.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

Cristal Therapeutics BV operates as a clinical stage pharmaceutical company. It develops nanomedicines based on its proprietary CriPec and CriPec ATN platform to treat diseases which include cancer. The company develops technology to transform drugs into nanoparticles. It also provides programs to develop nanomedicines for various therapeutic areas. The company was founded in 2011 and is based in Maastricht, the Netherlands.

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The company’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system to fight cancer.

InteRNA Technologies B.V. is a biotechnology company based in Nijmegen, the Netherlands, with a research and development center in Utrecht. Founded in 2006, the company focuses on developing microRNA (miRNA)-based therapeutics aimed at treating cancer. These drugs target previously undruggable pathways, enhancing the effectiveness of existing therapies and addressing drug resistance. InteRNA employs advanced techniques such as massively parallel sequencing and proprietary bioinformatics to analyze and validate miRNA sequences. Recently, the company secured additional equity financing to further advance its lead program for melanoma treatment, reflecting its commitment to innovation in oncology.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.